Author: Faron Pharmaceuticals

Posted Date:

March 9, 2026

Update to Faron’s Financial Calendar and Date of the Annual General Meeting in 2026

Faron Pharmaceuticals

March 9, 2026
CORRECTION: Faron Pharmaceuticals Ltd’s Annual Report 2025 published

Faron Pharmaceuticals

March 4, 2026
Faron’s Financial Statements Release 1 January to 31 December 2025

Faron Pharmaceuticals

March 4, 2026
Faron Pharmaceuticals Ltd’s Annual Report 2025 Published

Faron Pharmaceuticals

March 4, 2026
Faron Pharmaceuticals Ltd: Results of the Extraordinary General Meeting

Faron Pharmaceuticals

March 2, 2026
Faron and City of Hope in Process of Developing a Phase II Investigator-Initiated Trial of Bexmarilimab in Relapsed/Refractory MDS

Faron Pharmaceuticals

March 2, 2026
Faron’s Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026

Faron Pharmaceuticals

February 23, 2026
Faron Announces Phase II BEAM-X IIT Led by the Nordic AML Group Evaluating Bexmarilimab in Post-Transplant AML

Faron Pharmaceuticals

February 19, 2026
Faron Pharmaceuticals Ltd: Notice To The Extraordinary General Meeting

Faron Pharmaceuticals

February 9, 2026
New Review Published in Immunotherapy Highlights the Potential for Clever-1 Inhibition with bexmarilimab to Become the Cornerstone of Next-Generation, Multi-Indication Cancer Immunotherapy

Faron Pharmaceuticals

January 29, 2026